NEW YORK (GenomeWeb) – Sequenta said this week that biopharmaceutical firm Celgene and others have made an equity investment into the company. Sequenta told GenomeWeb Daily News that the investment is a Series D financing but declined to disclose the amount or identify the other investors. The funding will support incorporation of Sequenta's ClonoSight test into clinical trials of medicines in development for blood cancers. It also will go toward development of new clinical diagnostics based on the company's LymphoSight platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.